2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
6
Neuroblastoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Non-Hodgkin
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Fallopian Tube Neoplasms
2
Waldenstrom Macroglobulinemia
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Esophageal Neoplasms
1
Congenital Abnormalities
1
Interventions
Cyclophosphamide
25
Temozolomide
22
Vincristine
18
Irinotecan
18
Doxorubicin
13
Topotecan
10
Melphalan
10
Etoposide
10
Ifosfamide
8
Busulfan
8
cabozantinib
7
Magnetic Resonance Spectroscopy
7
Granulocyte Colony-Stimulating Factor
7
Filgrastim
6
regorafenib
5
fludarabine
5
X-Rays
5
Specimen Handling
5
Sirolimus
5
Radiotherapy
5
Gemcitabine
5
Drug Therapy
5
pegfilgrastim
4
palbociclib
4
liposomal doxorubicin
4
irinotecan sucrosofate
4
ganitumab
4
fludarabine phosphate
4
Trabectedin
4
Phantoms, Imaging
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Ewing
×
IL32 protein, human
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts